World Tuberculosis Day 2025—“Yes! We Can End TB: Commit, Invest, Deliver”, 24 March 2025

Tuberculosis is a disease that is both preventable and treatable, significantly affecting people’s health and quality of life worldwide. Every year, we commemorate World Tuberculosis Day to raise public awareness of the devastating health, social, and economic consequences of tuberculosis (TB) and to intensify efforts to end the global TB epidemic. The date signifies the day in 1882 when Dr. Robert Koch announced his discovery of the bacterium responsible for TB, which paved the way for diagnosing and curing this disease. We hope that established journals in the fields of Biology Life Sciences and Medicine & Pharmacology at MDPI, including Pathogens, Microorganisms, Reports, Medical Sciences, Healthcare and Diagnostics will continue to serve as a communication platform for innovative ideas regarding prevention and treatment.

“Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital”
by Virginia Di Bari, Carlotta Cerva, Raffaella Libertone, Serena Maria Carli, Maria Musso, Delia Goletti, Alessandra Aiello, Antonio Mazzarelli, Angela Cannas, Giulia Matusali, Fabrizio Palmieri, Gina Gualano and on behalf of the TB-INMI Working Group
Infect. Dis. Rep. 2025, 17(1), 11; https://doi.org/10.3390/idr17010011 

“Cigarette Smoking as a Risk Factor for Tuberculosis in Adults: Epidemiology and Aspects of Disease Pathogenesis”
by Charles Feldman, Annette J. Theron, Moloko C. Cholo and Ronald Anderson
Pathogens 2024, 13(2), 151; https://doi.org/10.3390/pathogens13020151 

“Situation Analysis of Early Implementation of Programmatic Management of Tuberculosis Preventive Treatment among Household Contacts of Pulmonary TB Patients in Delhi, India”
by Yasir Alvi, Sairu Philip, Tanu Anand, Palanivel Chinnakali, Farzana Islam, Neeta Singla, Pruthu Thekkur, Ashwani Khanna and BK Vashishat
Trop. Med. Infect. Dis. 2024, 9(1), 24; https://doi.org/10.3390/tropicalmed9010024 

“HLA-DPB1*05:01 and HLA-A*11:01 Is Associated with Adverse Drug Reactions to Isoniazid and Rifampin for Treatment of Latent Tuberculosis Infection in South Korea”
by Bomi Kim, Jungok Kim, Sun-Young Yoon, Hae Suk Cheong, Min-Jung Kwon, Joon-Sup Yeom, Han-Na Kim and Eun-Jeong Joo
Clin. Med. 2024, 13(12), 3563; https://doi.org/10.3390/jcm13123563 

“Pharmacists’ Role in Global TB Elimination: Practices, Pitfalls, and Potential”
by Alina Cernasev, Jonathan Stillo, Jolie Black, Mythili Batchu, Elaina Bell and Cynthia A. Tschampl
Healthcare 2024, 12(11), 1137; https://doi.org/10.3390/healthcare12111137 

“Metabolic Rewiring of Mycobacterium tuberculosis upon Drug Treatment and Antibiotics Resistance”
by Biplab Singha, Sumit Murmu, Tripti Nair, Rahul Singh Rawat, Aditya Kumar Sharma and Vijay Soni
Metabolites 2024, 14(1), 63; https://doi.org/10.3390/metabo14010063 

“Exploring the Impact of Silicosis Incidence on Tuberculosis Mortality and Morbidity: A Multi-Country Study”
by Muayad Albadrani
Med. Sci. 2023, 11(4), 63; https://doi.org/10.3390/medsci11040063